Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $4.2 million.

  • SAB Biotherapeutics' Accumulated Expenses rose 11.20% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 11.20%. This contributed to the annual value of $4.2 million for FY2024, which is 22.65% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Accumulated Expenses stood at $4.2 million for FY2024, which was up 22.65% from $3.4 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Accumulated Expenses peaked at $4.2 million during FY2024, and registered a low of $438,936 during FY2020.
  • Its 3-year average for Accumulated Expenses is $2.7 million, with a median of $3.4 million in 2023.
  • In the last 5 years, SAB Biotherapeutics' Accumulated Expenses declined by 24.15% in 2022 and then spiked by 564.32% in 2023.
  • SAB Biotherapeutics' Accumulated Expenses (Yearly) stood at $438,936 in 2020, then surged by 53.75% to $674,858 in 2021, then dropped by 24.15% to $511,849 in 2022, then surged by 564.32% to $3.4 million in 2023, then rose by 22.65% to $4.2 million in 2024.